IHH is an integrated healthcare group that offers patients a full and comprehensive range of medical services ranging from primary to quaternary as well as diagnostics, imaging, and rehabilitation.
The group employs 65,000 people and conducts its business through well-known brands such as Mount Elizabeth, Acibadem, Gleneagles, Parkway, and Fortis.
The group reported a mixed set of earnings for 2022.
Revenue creptup 5%year on year toRM 18 billionbut net operating incomefell by 13%year on year toRM 1.4 billion.
Net profitdeclined by 17%year on year toRM 1.5 billion.
Despite the weaker profit, IHH declared a final dividend ofS$0.0216for its Singapore shareholders,up 17%year on year.
This dividend will be paid on28 April.
The group expects inpatient revenue to increase in 2023 as more patients stream back into hospitals.
Its asset in Singapore, Mount Elizabeth Hospital, is also undergoing a major refurbishment since January this year to meet Singapore’s growing healthcare needs.
IHH also intends to develop its laboratory business into a platform that can provide end-to-end services for patients seeking seamless care.